OvaScience is a global life sciences company dedicated to improving fertility for women around the world.


Leadership Team

Executive Chairman, Chief Executive Officer and Co-founder

Dr. Dipp is the Executive Chairman and founding Chief Executive Officer of OvaScience. Dr. Dipp is also a Founder and Partner of Longwood Fund, a healthcare investment fund. Previously, Dr. Dipp was the Senior Vice President and Head of the CEEDD at GlaxoSmithKline. Prior, she was Vice President of Corporate Development at Sirtris prior to its acquisition by GSK. Before joining Sirtris, Dr. Dipp worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp serves on the Biotechnology Industry Organization’s (BIO) Emerging Companies Governing Board, the New England Venture Capital Association (NEVCA) Board, the Beth Israel Deaconess Medical Center Board of Directors, the Boston Symphony Orchestra Board of Overseers, and the MassBio Advisory Board. In March 2015, Dr. Dipp was elected to join the World Economic Forum’s Young Global Leaders (YGL). In September 2015, Dr. Dipp was named to Fortune magazine’s 40 Under 40 list.

Dr. Dipp holds an M.D. and a Ph.D. from the University of Oxford.

Chief Operating Officer

Mr. Chapman is the Chief Operating Officer of OvaScience. He joined from ArjoHuntleigh AB, a Sweden-based leading acute and long-term care equipment company, where he served as Regional President of North America. Prior to this role, Mr. Chapman served as President and CEO of Massachusetts-based diagnostic company Quanterix, where he oversaw growth including closing a global licensing deal with BioMérieux and a Series C financing round of more than $45 million. Mr. Chapman has also held executive leadership roles at EMD Millipore and Roche.

Mr. Chapman holds a Bachelor of Science in Microbiology from the University of Western Ontario, as well as a Bachelor of Science (hons) in Immunology from the University of Guelph Ontario. He also completed the Marketing Management Program at the Richard Ivey School of Business, University of Western Ontario.

Chief Financial Officer

Mr. Jeffrey Young is the Chief Financial Officer at OvaScience. Mr. Young joined OvaScience from Transmedics, Inc., where he served as Chief Financial Officer and Treasurer, leading the finance, accounting, tax and treasury functions. Prior to Transmedics, Mr. Young was CFO and Treasurer at Lantheus Medical Imaging, Inc. While at Lantheus, an international corporation, he was responsible for multiple functions, including finance, accounting, customer service, tax and treasury. He also assisted in raising $400 million in a registered notes offering. Before Lantheus, Mr. Young served as Chief Accounting Officer, Vice President of Finance and Treasurer at Critical Therapeutics, and managed the company’s transition during its acquisition by Cornerstone BioPharma. Earlier in his career, Mr. Young held finance roles at PerkinElmer, Inc. and PricewaterhouseCoopers.

Mr. Young is a Certified Public Accountant and holds a B.S. in Business Administration from Georgetown University.